Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Therapies in the Treatment of Uterine Serous Carcinoma.
Tymon-Rosario JR, Gorman M, Santin AD. Tymon-Rosario JR, et al. Curr Treat Options Oncol. 2022 Dec;23(12):1804-1817. doi: 10.1007/s11864-022-01030-7. Epub 2022 Nov 30. Curr Treat Options Oncol. 2022. PMID: 36447064 Review.
Immunotherapy in Cervical Cancer.
Mauricio D, Zeybek B, Tymon-Rosario J, Harold J, Santin AD. Mauricio D, et al. Curr Oncol Rep. 2021 Apr 14;23(6):61. doi: 10.1007/s11912-021-01052-8. Curr Oncol Rep. 2021. PMID: 33852056 Review.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Yadav G, et al. Gynecol Oncol. 2022 Aug;166(2):351-357. doi: 10.1016/j.ygyno.2022.05.021. Epub 2022 May 28. Gynecol Oncol. 2022. PMID: 35641325
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, Bianchi A, Zammataro L, Manzano A, Bonazzoli E, Manara P, Buza N, Hui P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Lopez S, Santin AD. Han C, et al. Gynecol Oncol. 2020 Feb;156(2):430-438. doi: 10.1016/j.ygyno.2019.11.018. Epub 2019 Dec 12. Gynecol Oncol. 2020. PMID: 31839338
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Perrone E, et al. Mol Oncol. 2020 Mar;14(3):645-656. doi: 10.1002/1878-0261.12627. Epub 2020 Jan 14. Mol Oncol. 2020. PMID: 31891442 Free PMC article.
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A, Zammataro L, Manzano A, Manara P, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Raspagliesi F, Angioli R, Buza N, Hui P, Bond HM, Santin AD. Lopez S, et al. Oncotarget. 2020 Feb 4;11(5):560-570. doi: 10.18632/oncotarget.27342. eCollection 2020 Feb 4. Oncotarget. 2020. PMID: 32082489 Free PMC article.
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Perrone E, et al. Front Oncol. 2020 Feb 12;10:118. doi: 10.3389/fonc.2020.00118. eCollection 2020. Front Oncol. 2020. PMID: 32117765 Free PMC article.
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
Bonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Bonazzoli E, et al. Gynecol Oncol. 2020 Sep;158(3):769-775. doi: 10.1016/j.ygyno.2020.06.484. Epub 2020 Jun 26. Gynecol Oncol. 2020. PMID: 32600791 Free PMC article.
44 results